Clinical Trials Logo

EGFR-TKI clinical trials

View clinical trials related to EGFR-TKI.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03428022 Recruiting - NSCLC Clinical Trials

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

AFLC
Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors(EGFR-TKI)resistance will be treated with Apatinib and EGFR-TKI. The primary objective is the disease progression free survival of the patients.